Logo

Surgeons now have a faster way to assess whether breast cancer has spread, thanks to the FDA's approval of the first molecular test to detect metastatic breast cancer. During the patient's lumpectomy or mastectomy, surgeons traditionally examine the lymph node closest to the breast — the sentinel node — for signs of metastases. If the tissue is examined immediately and tumor cells are discovered, additional lymph nodes are taken out — but, usually, further and more extensive microscopic testing is required to confirm that cancer has spread. Problem is the lab results take up to two days to come back, which leaves women in limbo before possibly facing a second surgery. But with the new test, called GeneSearch BLN Assay, doctors can accurately test the sentinel node for metastases during the initial surgery by measuring molecular markers of breast cancer that are abundant in cancerous breast tissue but normally scarce in lymph nodes. If the test shows the presence of cancer, the physician can remove affected lymph nodes immediately, sparing women the wait and possible follow-up surgery.